Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Urology. 2009 May 9;74(2):446–451. doi: 10.1016/j.urology.2009.01.023

Figure 1.

Figure 1

Immunocytochemistry of quantum dot (QD)800 binding activity in cultured prostate cancer (PCa) cells. (A) Phase contrast of prostate-specific membrane antigen (PSMA)-positive C4-2B cells and PSMA-negative PC3 cells in culture. (B) Spectrophotometry analysis of positive binding of QD800 conjugates on surface of PSMA-positive C4-2B cells. Negative staining in PC3 cells, which lacked PSMA expression. (C) Positive binding of C4-2B cells to QD800 in cell pellet. Control PC3 cells did not bind to probe (Xenogen IVIS Imaging System).